(Q36537911)

14 August 2017

1 reference

title

HIV/AIDS pathogenesis and treatment: new twists and turns (English)

1 reference

14 August 2017

1 reference

1 reference

https://api.crossref.org/works/10.1016/0952-7915(91)90017-U

28 October 2022

author name string

A. J. Pinching

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1684509

28 October 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1684509

28 October 2022

publication date

1 August 1991

1 reference

full work available at URL

14 August 2017

https://api.elsevier.com/content/article/PII:095279159190017U?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0952-7915(91)90017-U

https://api.elsevier.com/content/article/PII:095279159190017U?httpAccept=text/plain

28 October 2022

1 reference

https://api.crossref.org/works/10.1016/0952-7915(91)90017-U

Current Opinion in Immunology

28 October 2022

published in

1 reference

14 August 2017

volume

3

1 reference

14 August 2017

issue

4

1 reference

14 August 2017

page(s)

537-542

1 reference

Pathogenesis of infection with human immunodeficiency virus

14 August 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1016/0952-7915(91)90017-U

HLA haplotype A1 B8 DR3 as a risk factor for HIV-related disease

28 October 2022

2

1 reference

https://api.crossref.org/works/10.1016/0952-7915(91)90017-U

A1, Cw7, B8, DR3 HLA antigen combination associated with rapid decline of T-helper lymphocytes in HIV-1 infection. A report from the Multicenter AIDS Cohort Study

28 October 2022

3

1 reference

https://api.crossref.org/works/10.1016/0952-7915(91)90017-U

HIV-1 transmission and function of virus-infected monocytes/macrophages

28 October 2022

6

1 reference

https://api.crossref.org/works/10.1016/0952-7915(91)90017-U

Susceptibility of human peripheral blood dendritic cells to infection by human immunodeficiency virus

28 October 2022

7

1 reference

https://api.crossref.org/works/10.1016/0952-7915(91)90017-U

Detection of three distinct patterns of T helper cell dysfunction in asymptomatic, human immunodeficiency virus-seropositive patients. Independence of CD4+ cell numbers and clinical staging

28 October 2022

9

1 reference

https://api.crossref.org/works/10.1016/0952-7915(91)90017-U

HIV envelope glycoprotein, antigen specific T-cell responses, and soluble CD4

28 October 2022

10

1 reference

https://api.crossref.org/works/10.1016/0952-7915(91)90017-U

Human immunodeficiency virus-associated changes in signal transduction

28 October 2022

11

1 reference

https://api.crossref.org/works/10.1016/0952-7915(91)90017-U

HIV-1-infected T cells show a selective signaling defect after perturbation of CD3/antigen receptor

28 October 2022

12

1 reference

https://api.crossref.org/works/10.1016/0952-7915(91)90017-U

Lymphocyte activation by HIV-1 envelope glycoprotein

28 October 2022

13

1 reference

https://api.crossref.org/works/10.1016/0952-7915(91)90017-U

Synergism between HIV gp120 and gp120-specific antibody in blocking human T cell activation

28 October 2022

14

1 reference

https://api.crossref.org/works/10.1016/0952-7915(91)90017-U

Human immunodeficiency virus type 1 envelope glycoprotein gp120 produces immune defects in CD4+ T lymphocytes by inhibiting interleukin 2 mRNA

28 October 2022

17

1 reference

https://api.crossref.org/works/10.1016/0952-7915(91)90017-U

Human immunodeficiency virus-1 glycoproteins gp120 and gp160 specifically inhibit the CD3/T cell-antigen receptor phosphoinositide transduction pathway

28 October 2022

18

1 reference

https://api.crossref.org/works/10.1016/0952-7915(91)90017-U

HIV inhibits the early steps of lymphocyte activation, including initiation of inositol phospholipid metabolism

28 October 2022

19

1 reference

https://api.crossref.org/works/10.1016/0952-7915(91)90017-U

Lymphocytes from HIV-infected individuals show aberrant inositol polyphosphate metabolism which reverses after zidovudine therapy

28 October 2022

20

1 reference

https://api.crossref.org/works/10.1016/0952-7915(91)90017-U

The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group

28 October 2022

23

1 reference

https://api.crossref.org/works/10.1016/0952-7915(91)90017-U

Declining incidence of AIDS dementia complex after introduction of zidovudine treatment

28 October 2022

24

1 reference

https://api.crossref.org/works/10.1016/0952-7915(91)90017-U

Vesicular changes in the myopathies of AIDS. Ultrastructural observations and their relationship to zidovudine treatment

28 October 2022

25

1 reference

https://api.crossref.org/works/10.1016/0952-7915(91)90017-U

Mitochondrial myopathy caused by long-term zidovudine therapy

28 October 2022

26

1 reference

https://api.crossref.org/works/10.1016/0952-7915(91)90017-U

A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group

28 October 2022

27

1 reference

https://api.crossref.org/works/10.1016/0952-7915(91)90017-U

A pilot study of low-dose zidovudine in human immunodeficiency virus infection

28 October 2022

28

1 reference

https://api.crossref.org/works/10.1016/0952-7915(91)90017-U

HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy

28 October 2022

29

1 reference

https://api.crossref.org/works/10.1016/0952-7915(91)90017-U

Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT)

28 October 2022

30

1 reference

https://api.crossref.org/works/10.1016/0952-7915(91)90017-U

Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases

28 October 2022

31

1 reference

https://api.crossref.org/works/10.1016/0952-7915(91)90017-U

In vivo activity against HIV and favorable toxicity profile of 2',3'-dideoxyinosine

28 October 2022

33

1 reference

https://api.crossref.org/works/10.1016/0952-7915(91)90017-U

2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trial

28 October 2022

34

1 reference

https://api.crossref.org/works/10.1016/0952-7915(91)90017-U

Once-daily administration of 2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. Results of a Phase I trial

28 October 2022

35

1 reference

https://api.crossref.org/works/10.1016/0952-7915(91)90017-U

Long-term toxicity/activity profile of 2',3'-dideoxyinosine in AIDS or AIDS-related complex

28 October 2022

36

1 reference

https://api.crossref.org/works/10.1016/0952-7915(91)90017-U

Phase I studies of 2',3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT).

28 October 2022

37

1 reference

https://api.crossref.org/works/10.1016/0952-7915(91)90017-U

Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives

28 October 2022

38

1 reference

https://api.crossref.org/works/10.1016/0952-7915(91)90017-U

Inhibition of HIV-1 protease in infected T-lymphocytes by synthetic peptide analogues

28 October 2022

40

1 reference

https://api.crossref.org/works/10.1016/0952-7915(91)90017-U

A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation

28 October 2022

41

1 reference

https://api.crossref.org/works/10.1016/0952-7915(91)90017-U

Rational design of peptide-based HIV proteinase inhibitors

28 October 2022

42

1 reference

https://api.crossref.org/works/10.1016/0952-7915(91)90017-U

The safety and pharmacokinetics of GLQ223 in subjects with AIDS and AIDS-related complex: a phase I study.

28 October 2022

43

1 reference

https://api.crossref.org/works/10.1016/0952-7915(91)90017-U

A phase I/II study of trichosanthin treatment of HIV disease

28 October 2022

44

1 reference

https://api.crossref.org/works/10.1016/0952-7915(91)90017-U

Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase I-II escalating dosage trial

28 October 2022

48

1 reference

https://api.crossref.org/works/10.1016/0952-7915(91)90017-U

The safety and pharmacokinetics of recombinant soluble CD4 (rCD4) in subjects with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase 1 study.

28 October 2022

49

1 reference

https://api.crossref.org/works/10.1016/0952-7915(91)90017-U

Biological properties of a CD4 immunoadhesin

28 October 2022

50

1 reference

https://api.crossref.org/works/10.1016/0952-7915(91)90017-U

28 October 2022

Identifiers

1 reference

14 August 2017

1 reference